OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	120
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	101
Metabolically healthy obese and MAFLD: does weight status alone matter?	90
Platelets in acute liver failure: an innocent bystander or instigator?	86
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	68
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	67
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	65
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	57
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	57
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	49
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	47
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	46
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	45
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	44
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	44
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	43
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	41
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	39
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	38
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	38
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	37
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	35
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	35
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	35
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	34

Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	34
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	34
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	34
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	32
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	32
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	32
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	31
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	31
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	31
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	31